Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation

Journal of Rheumatology

Volumn 29, Issue 7, 2002, Pages 1430-1436

  Grisar, Johannes ^a   Bernecker, Peter M ^a   Aringer, Martin ^a   Redlich, Kurt ^a   Sedlak, Markus ^a   Wolozcszuk, Wolfgang ^a   Spitzauer, Susanne ^a   Grampp, Stephan ^a   Kainberger, Franz ^a   Ebner, Wolfgang ^a   Smolen, Josef S ^a   Pietschmann, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ankylosing spondylitis psoriatic arthritis; Osteoporosis; Reactive arthritis osteoprotegerin; Seronegative spondyloarthropathies

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; OSTEOPROTEGERIN; AMINO ACID; BIOLOGICAL MARKER; CELL RECEPTOR; GLYCOPROTEIN; OSTEOCALCIN; TNFRSF11B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS LINKING; DUAL ENERGY X RAY ABSORPTIOMETRY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; URINE LEVEL; ADOLESCENT; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; HOSPITALIZATION; MIDDLE AGED; PHYSIOLOGY; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDY; RADIODENSITOMETRY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AMINO ACIDS; ARTHRITIS, PSORIATIC; ARTHRITIS, REACTIVE; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; COHORT STUDIES; COMPARATIVE STUDY; DENSITOMETRY, X-RAY; FEMALE; GLYCOPROTEINS; HUMAN; MALE; MIDDLE AGE; OSTEOCALCIN; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; SUPPORT, NON-U.S. GOV'T; TUMOR NECROSIS FACTOR; HUMANS; MIDDLE AGED; OSTEOPROTEGERIN; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035992944     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Osteoporosis associated with rheumatoid arthritis: Pathogenesis and management
2. Generalised and localised bone loss in patients with rheumatoid arthritis
3. Epidemiology of bone loss
4. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis
5. Interaction between nitric oxide synthase and cyclooxygenase pathways in osteoblastic MC3T3-E1 cells
6. Effects of interleukin-1 on bone turnover in normal mice
7. Local and systemic factors in the pathogenesis of osteoporosis
8. Stromelysin (MMP-3) synthesis is upregulated in estrogen-deficient mouse osteoblasts in vivo and in vitro
9. Glucocorticoid-induced osteoporosis
10. The effect of cyclosporin A administration on bone metabolism in the rat evaluated by biochemical markers
11. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behcet's syndrome
12. Psoriatic arthritis: A unique family
13. Classification of inflammatory arthritis by enthesitis
14. Enthesitis in spondyloarthropathy
15. Serum osteocalcin levels in patients with psoriatic arthritis: An extended report
16. Radiologic diagnosis and pathology of the spondyloarthropathies
17. Spinal fractures complicating ankylosing spondylitis
18. Spinal fractures complicating ankylosing spondylitis. A long-term follow up study
19. Fracture risk in patients with ankylosing spondylitis: A population based study
20. Bone mass in ankylosing spondylitis
21. Axial and peripheral osteopenia in ankylosing spondylitis
22. Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis
23. Significant loss of bone mass in patients with early, active ankylosing spondylitis: A followup study
24. Biochemical markers of bone turnover in seronegative spondylarthropathy: Relationship to disease activity
25. Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures
26. Bone mineral density in patients with peripheral psoriatic arthritis
27. Studies on psoriatic osteopathy
28. Serum bone Gla-protein: A specific marker for bone formation in postmenopausal osteoporosis
29. Osteocalcin and bone morphometric parameters in adults without bone disease
30. Markers of bone formation and resorption
31. Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation with bone histomorphometry
32. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis
33. Bone turnover markers and sex hormones in men with idiopathic osteoporosis
34. Rapid bone loss is associated with increased levels of biochemical markers
35. Sex steroids, biochemical markers, bone mineral density and histomorphometry in male osteoporosis patients
36. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
37. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
38. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Downregulation by glucocorticoids
39. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
40. New York clinical criteria for ankylosing spondylitis. A statistical evaluation
41. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy
42. Reiter's syndrome and reactive arthritis
43. Osteoprotegerin serum levels in men: Correlation with age, estrogen, and testosterone status
44. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis
45. Serum osteocalcin as an index of bone turnover in active rheumatoid arthritis and in active psoriatic arthritis
46. Biochemical markers to survey bone turnover
47. Clinical application of biochemical markers of bone metabolism
48. Rapid bone loss is associated with increased levels of biochemical markers
49. Biochemical markers of bone turnover in Paget's disease of bone
50. The use of biochemical markers of bone turnover in osteoporosis
51. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: Loss of antigenicity by treatment with cathepsin K
52. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers
53. Factors influencing bone loss in rheumatoid arthritis: A longitudinal study
54. Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis
55. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis
56. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis?
57. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2 and cytokines
58. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: A close correlation between serum IL-6 and disease activity and severity
59. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid
60. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab
61. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: An open pilot study
62. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function